CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioBehavioral Diagnostics Company (BioBDx) today unveiled its new Quotient™ ADHD System. The Quotient™ ADHD System is the first FDA-cleared test that offers medical professionals a private, office-based capability to quickly, objectively and accurately measure a child’s inability to inhibit abnormal levels of motor activity, sustain attention, and suppress impulsive response. Deficits in these neurological control functions are directly related to the core symptom domains of Attention Deficit Hyperactivity Disorder (ADHD): hyperactivity, inattention and impulsivity.
